News & Opinion
Healx CSO presents results at CDKL5 Forum conference
An exciting collaboration, between Healx and the University of Insubria has identified a new repurposing candidate for CDKL5 (cyclin-dependent kinase-like 5) deficiency. This is a rare X-linked condition giving rise to seizures that begin in the first few months of life. Most patients cannot walk, talk, or feed themselves, and many are confined to wheelchairs. The findings will be presented by Healx Chief Scientific Officer Dr David Cavalla, at the forthcoming CDKL5 Forum conference in London on October 10 and 11. Further information will be made available following the conference.
This work was supported by a research grant from the University of Pennsylvania Orphan Disease Center on behalf of Loulou Foundation.